HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced that a newly published clinical case study has demonstrated the successful use of its 308-nanometer excimer laser in treating a rare subtype of cutaneous T-cell lymphoma known as poikilodermatous mycosis fungoides (pMF). The study, published in Case Reports in Oncology, is the first English-language report to confirm the excimer laser’s efficacy in this difficult-to-treat form of mycosis fungoides (MF).
The research, conducted by dermatology specialists at Tohoku University Graduate School of Medicine in Japan, showed full lesion resolution after treatment with the excimer laser. The patient, who had failed to respond to topical corticosteroids and vitamin D analogs, achieved complete clearance of erythema after five laser sessions over three months.
“The XTRAC Excimer laser continues to draw attention worldwide for its versatility in treating inflammatory skin conditions,” said Dr. Dolev Rafaeli, Strata President and CEO. “It is that versatility, both in monotherapy and in combination with multiple medications, that has resulted in the Centers for Medicare and Medicaid Services (CMS) significantly expanding the reimbursement codes for a much wider variety of these conditions, including MF and pMF as outlined in this study, as well as every autoimmune-based skin condition. It is important to note that independent investigators continue testing the limits of XTRAC therapy, and publication after publication verifies the clinical track record of the device, whether in patients in the U.S. or worldwide. It is worth noting that Japan, where this study was conducted, is a significant market for the XTRAC Excimer laser as dermatologists there are at the cutting edge of pioneering new uses for the technology. We continue to work closely with CMS in obtaining the expanded reimbursement for XTRAC and will continue to provide updates as they develop.”
Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, a rare cancer of the immune T cells that affects the skin. The poikilodermatous variant is particularly uncommon and challenging to manage, often resistant to standard therapies such as narrowband UVB and PUVA phototherapy.
The excimer laser delivers concentrated ultraviolet B light at 308 nanometers, enabling physicians to target specific lesions without exposing unaffected skin. Unlike conventional phototherapy, this targeted approach minimizes cumulative exposure and treatment-related risks while achieving rapid and durable responses.
In addition to this new case study, a 2023 systematic review published in the International Journal of Dermatology found that excimer laser therapy achieved complete clinical responses in more than 70% of MF patients, with minimal adverse effects and rare relapse.
STRATA noted that Japan represents a key market for its excimer laser technology, with clinicians there at the forefront of developing new dermatologic applications. The company said it will continue collaborating with regulators and medical partners to broaden the device’s therapeutic use and reimbursement coverage in the United States.
The findings mark another milestone for STRATA’s XTRAC technology, strengthening its position as a versatile, noninvasive treatment for a wide range of dermatologic and immune-related skin conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.